A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies

Susan P. Perrine, Olivier Hermine, Trudy Small, Felipe Suarez, Richard O'Reilly, Farid Boulad, Joyce Fingeroth, Melissa Askin, Arthur Levy, Steven J. Mentzer, Massimo Di Nicola, Alessandro M. Gianni, Christoph Klein, Steven Horwitz, Douglas V. Faller

Research output: Contribution to journalArticle

181 Citations (Scopus)

Abstract

Malignancies associated with latent Epstein-Barr virus (EBV) are resistant to nucleoside-type antiviral agents because the viral enzymetarget of these antiviral drugs, thymidine kinase (TK), is not expressed. Short-chain fatty acids, such as butyrate, induce EBV-TK expression in latently infected B cells. As butyrate has been shown to sensitize EBV+ lymphoma cells in vitro to apoptosis induced by ganciclovir, arginine butyrate in combination with ganciclovir was administered in 15 patients with refractory EBV+ lymphoid malignancies to evaluate the drug combination for toxicity, pharmacokinetics, and clinical responses. Ganciclovir was administered twice daily at standard doses, and arginine butyrate was administered by continuous infusion in an intrapatient dose escalation, from 500 mg/(kg/day) escalating to 2000 mg/(kg/day), as tolerated, for a 21-day cycle. The MTD for arginine butyrate in combination with ganciclovir was established as 1000 mg/(kg/day). Ten of 15 patients showed significant antitumor responses, with 4 CRs and 6 PRs within one treatment cycle. Complications from rapid tumor lysis occurred in 3 patients. Reversible somnolence or stupor occurred in 3 patients at arginine butyrate doses of greater than 1000 mg/(kg/day). The combination of arginine butyrate and ganciclovir was reasonably well-tolerated and appears to have significant biologic activity in vivo in EBV+ lymphoid malignancies which are refractory to other regimens.

Original languageEnglish
Pages (from-to)2571-2578
Number of pages8
JournalBlood
Volume109
Issue number6
DOIs
Publication statusPublished - Mar 15 2007

Fingerprint

Ganciclovir
Human Herpesvirus 4
Viruses
Thymidine Kinase
Butyrates
Neoplasms
Refractory materials
Antiviral Agents
Stupor
Pharmacokinetics
Volatile Fatty Acids
Drug Combinations
Drug-Related Side Effects and Adverse Reactions
Nucleosides
Toxicity
Tumors
Lymphoma
B-Lymphocytes
Cells
arginine butyrate

ASJC Scopus subject areas

  • Hematology

Cite this

Perrine, S. P., Hermine, O., Small, T., Suarez, F., O'Reilly, R., Boulad, F., ... Faller, D. V. (2007). A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood, 109(6), 2571-2578. https://doi.org/10.1182/blood-2006-01-024703

A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. / Perrine, Susan P.; Hermine, Olivier; Small, Trudy; Suarez, Felipe; O'Reilly, Richard; Boulad, Farid; Fingeroth, Joyce; Askin, Melissa; Levy, Arthur; Mentzer, Steven J.; Di Nicola, Massimo; Gianni, Alessandro M.; Klein, Christoph; Horwitz, Steven; Faller, Douglas V.

In: Blood, Vol. 109, No. 6, 15.03.2007, p. 2571-2578.

Research output: Contribution to journalArticle

Perrine, SP, Hermine, O, Small, T, Suarez, F, O'Reilly, R, Boulad, F, Fingeroth, J, Askin, M, Levy, A, Mentzer, SJ, Di Nicola, M, Gianni, AM, Klein, C, Horwitz, S & Faller, DV 2007, 'A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies', Blood, vol. 109, no. 6, pp. 2571-2578. https://doi.org/10.1182/blood-2006-01-024703
Perrine, Susan P. ; Hermine, Olivier ; Small, Trudy ; Suarez, Felipe ; O'Reilly, Richard ; Boulad, Farid ; Fingeroth, Joyce ; Askin, Melissa ; Levy, Arthur ; Mentzer, Steven J. ; Di Nicola, Massimo ; Gianni, Alessandro M. ; Klein, Christoph ; Horwitz, Steven ; Faller, Douglas V. / A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. In: Blood. 2007 ; Vol. 109, No. 6. pp. 2571-2578.
@article{02f4de925e314617a4727abcbc9019f8,
title = "A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies",
abstract = "Malignancies associated with latent Epstein-Barr virus (EBV) are resistant to nucleoside-type antiviral agents because the viral enzymetarget of these antiviral drugs, thymidine kinase (TK), is not expressed. Short-chain fatty acids, such as butyrate, induce EBV-TK expression in latently infected B cells. As butyrate has been shown to sensitize EBV+ lymphoma cells in vitro to apoptosis induced by ganciclovir, arginine butyrate in combination with ganciclovir was administered in 15 patients with refractory EBV+ lymphoid malignancies to evaluate the drug combination for toxicity, pharmacokinetics, and clinical responses. Ganciclovir was administered twice daily at standard doses, and arginine butyrate was administered by continuous infusion in an intrapatient dose escalation, from 500 mg/(kg/day) escalating to 2000 mg/(kg/day), as tolerated, for a 21-day cycle. The MTD for arginine butyrate in combination with ganciclovir was established as 1000 mg/(kg/day). Ten of 15 patients showed significant antitumor responses, with 4 CRs and 6 PRs within one treatment cycle. Complications from rapid tumor lysis occurred in 3 patients. Reversible somnolence or stupor occurred in 3 patients at arginine butyrate doses of greater than 1000 mg/(kg/day). The combination of arginine butyrate and ganciclovir was reasonably well-tolerated and appears to have significant biologic activity in vivo in EBV+ lymphoid malignancies which are refractory to other regimens.",
author = "Perrine, {Susan P.} and Olivier Hermine and Trudy Small and Felipe Suarez and Richard O'Reilly and Farid Boulad and Joyce Fingeroth and Melissa Askin and Arthur Levy and Mentzer, {Steven J.} and {Di Nicola}, Massimo and Gianni, {Alessandro M.} and Christoph Klein and Steven Horwitz and Faller, {Douglas V.}",
year = "2007",
month = "3",
day = "15",
doi = "10.1182/blood-2006-01-024703",
language = "English",
volume = "109",
pages = "2571--2578",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "6",

}

TY - JOUR

T1 - A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies

AU - Perrine, Susan P.

AU - Hermine, Olivier

AU - Small, Trudy

AU - Suarez, Felipe

AU - O'Reilly, Richard

AU - Boulad, Farid

AU - Fingeroth, Joyce

AU - Askin, Melissa

AU - Levy, Arthur

AU - Mentzer, Steven J.

AU - Di Nicola, Massimo

AU - Gianni, Alessandro M.

AU - Klein, Christoph

AU - Horwitz, Steven

AU - Faller, Douglas V.

PY - 2007/3/15

Y1 - 2007/3/15

N2 - Malignancies associated with latent Epstein-Barr virus (EBV) are resistant to nucleoside-type antiviral agents because the viral enzymetarget of these antiviral drugs, thymidine kinase (TK), is not expressed. Short-chain fatty acids, such as butyrate, induce EBV-TK expression in latently infected B cells. As butyrate has been shown to sensitize EBV+ lymphoma cells in vitro to apoptosis induced by ganciclovir, arginine butyrate in combination with ganciclovir was administered in 15 patients with refractory EBV+ lymphoid malignancies to evaluate the drug combination for toxicity, pharmacokinetics, and clinical responses. Ganciclovir was administered twice daily at standard doses, and arginine butyrate was administered by continuous infusion in an intrapatient dose escalation, from 500 mg/(kg/day) escalating to 2000 mg/(kg/day), as tolerated, for a 21-day cycle. The MTD for arginine butyrate in combination with ganciclovir was established as 1000 mg/(kg/day). Ten of 15 patients showed significant antitumor responses, with 4 CRs and 6 PRs within one treatment cycle. Complications from rapid tumor lysis occurred in 3 patients. Reversible somnolence or stupor occurred in 3 patients at arginine butyrate doses of greater than 1000 mg/(kg/day). The combination of arginine butyrate and ganciclovir was reasonably well-tolerated and appears to have significant biologic activity in vivo in EBV+ lymphoid malignancies which are refractory to other regimens.

AB - Malignancies associated with latent Epstein-Barr virus (EBV) are resistant to nucleoside-type antiviral agents because the viral enzymetarget of these antiviral drugs, thymidine kinase (TK), is not expressed. Short-chain fatty acids, such as butyrate, induce EBV-TK expression in latently infected B cells. As butyrate has been shown to sensitize EBV+ lymphoma cells in vitro to apoptosis induced by ganciclovir, arginine butyrate in combination with ganciclovir was administered in 15 patients with refractory EBV+ lymphoid malignancies to evaluate the drug combination for toxicity, pharmacokinetics, and clinical responses. Ganciclovir was administered twice daily at standard doses, and arginine butyrate was administered by continuous infusion in an intrapatient dose escalation, from 500 mg/(kg/day) escalating to 2000 mg/(kg/day), as tolerated, for a 21-day cycle. The MTD for arginine butyrate in combination with ganciclovir was established as 1000 mg/(kg/day). Ten of 15 patients showed significant antitumor responses, with 4 CRs and 6 PRs within one treatment cycle. Complications from rapid tumor lysis occurred in 3 patients. Reversible somnolence or stupor occurred in 3 patients at arginine butyrate doses of greater than 1000 mg/(kg/day). The combination of arginine butyrate and ganciclovir was reasonably well-tolerated and appears to have significant biologic activity in vivo in EBV+ lymphoid malignancies which are refractory to other regimens.

UR - http://www.scopus.com/inward/record.url?scp=33947275876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947275876&partnerID=8YFLogxK

U2 - 10.1182/blood-2006-01-024703

DO - 10.1182/blood-2006-01-024703

M3 - Article

VL - 109

SP - 2571

EP - 2578

JO - Blood

JF - Blood

SN - 0006-4971

IS - 6

ER -